Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | IL2 | P60568 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
| ▸ | EED | O75530 | 1/20 | 0.33 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2090711 | 0.81 | KDM4E (0.46) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL471858 | 0.80 | KDM4E (0.60) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL2088974 | 0.80 | KDM4E (0.51) | LMNAHTTMAPTKDM4EHRH3 | |
| Hydrochloric Acid SCHEMBL5740210 | 0.79 | KDM4E (0.45) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL20410849 | 0.79 | KDM4E (0.49) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL6189074 | 0.79 | HRH3 (0.48) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL6205697 | 0.78 | HRH3 (0.44) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL6050408 | 0.78 | HRH3 (0.44) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL20410969 | 0.78 | KDM4E (0.51) | LMNAHTTMAPTKDM4EHRH3 | |
| SCHEMBL20409590 | 0.78 | KDM4E (0.53) | LMNAHTTMAPTKDM4EHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1572655-A2 | NOVEL ARYLHETEROALKYLAMINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-14 | — | — | EP | disclosed |
| CN-1630637-A | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2005-06-22 | — | — | CN | disclosed |
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | ASTRAZENECA AB (SE) | 2004-12-02 | — | — | US | disclosed |
| WO-2002090332-A2 | NOVEL AEYLHETEROALKYLAMINΕ DERIVATIVES | ASTRAZENECA AB (SE) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242871-A1 | Novel arylheteroalkylamine derivatives | CYP1A1, NOS3, NOS1 | LMNA 3940/4885HTT 2425/4885MAPT 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.